SCHEMBL24924079

SCHEMBL24924079

O=C1CCC(c2cccnc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 0.56
KDM4E B2RXH2 2/20 0.49
CYP3A4 P08684 1/20 0.49
THRB P10828 1/20 0.49
TSHR P16473 1/20 0.49
THPO P40225 1/20 0.49
MEN1 O00255 1/20 0.49
MAPK1 P28482 1/20 0.49
KMT2A Q03164 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
CHRNB2 P17787 6/20 0.47
CHRNA4 P43681 6/20 0.47
ALDH1A1 P00352 3/20 0.45
CHRNA7 P36544 5/20 0.44
CHRNB4 P30926 2/20 0.44
CHRNA3 P32297 2/20 0.44
CHRNA2 Q15822 2/20 0.44
CYP2A6 P11509 2/20 0.44
LMNA P02545 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1070252 0.90 CYP11B2 (0.62) CYP11B2KDM4ECYP3A4THRBTSHR
SCHEMBL746253 0.89 CYP11B2 (0.65) CYP11B2KDM4ECYP3A4THRBTSHR
Ethylene SCHEMBL3240169 0.86 CYP11B2 (0.61) CYP11B2KDM4ECYP3A4THRBTSHR
SCHEMBL26422507 0.85 CYP11B2 (0.58) CYP11B2KDM4ECYP3A4THRBTSHR
SCHEMBL25048756 0.84 CYP11B2 (0.47) CYP11B2CYP3A4MEN1ALDH1A1CYP2A6
SCHEMBL13453993 0.82 MAPT (0.60) CYP11B2KDM4ECYP3A4THRBTSHR
Acetic Acid SCHEMBL27994757 0.81 CYP11B2 (0.54) CYP11B2KDM4ECYP3A4THRBTSHR
SCHEMBL24924065 0.78 PDE3B (0.46) CYP11B2LMNAMAPTSMN1; SMN2
SCHEMBL4864740 0.77 GAA (0.63) TSHRMAPK1LMNAMAPTPOLB
SCHEMBL568689 0.77 GAA (0.63) TSHRMAPK1LMNAMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030869-B2 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2024-07-09 US disclosed
US-12030869-B2 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2024-07-09 US disclosed
US-20240150324-A1 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV ASSEMBLY BIOSCIENCES, INC. 2024-05-09 US disclosed
US-11560370-B1 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2023-01-24 US disclosed
US-11560370-B1 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2023-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11560370-B1 5-membered heteroaryl carboxamide compounds for treatment of HBV HCCS, HAVCR2, MAVS CYP11B2 1999/4885KDM4E 1967/4885CYP3A4 2535/4885
US-20240150324-A1 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV HCCS, HAVCR2, MAVS CYP11B2 1999/4885KDM4E 1967/4885CYP3A4 2535/4885
US-12030869-B2 5-membered heteroaryl carboxamide compounds for treatment of HBV HCCS, HAVCR2, MAVS CYP11B2 1999/4885KDM4E 1967/4885CYP3A4 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.